All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sentinel Lymph Node Biopsy Omission Shows Feasibility in Select HR+ Breast Cancer

December 15th 2025

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer

December 15th 2025

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in R/R Myeloma

December 15th 2025

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

UCSF Study Finds a Better Way to Screen for Breast Cancer

December 15th 2025

Researchers at UCSF share results about individualized breast cancer screenings from the WISDOM study.

Varegacestat Hits Phase 3 PFS End Point in Progressing Desmoid Tumors

December 15th 2025

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis

December 15th 2025

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes

December 15th 2025

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Five Under 5: Top Oncology Videos for the Week of 12/7

December 14th 2025

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

Talquetamab Plus Pomalidomide Maintains Deep, Durable Responses in R/R Multiple Myeloma

December 14th 2025

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

DREAMM-8 Study Triplet Sustains PFS, MRD-negativity in R/R Multiple Myeloma

December 14th 2025

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 12/7

December 13th 2025

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer

December 13th 2025

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer

December 12th 2025

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Neoadjuvant Niraparib Plus Dostarlimab Delivers 50% pCR Rate in BRCA+ or PALB2+ TNBC

December 12th 2025

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

Giredestrant-Based Combo Boosts PFS Across Subgroups in Advanced ER+/HER2– Breast Cancer After CDK4/6 Inhibition

December 12th 2025

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

Sacituzumab Govitecan Plus Pembrolizumab Yields Predictable, Manageable Safety Profile in TNBC

December 12th 2025

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC

December 12th 2025

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

Menopausal HRT Does Not Influence Breast Cancer Risk in Women Harboring BRCA Variants

December 12th 2025

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

Mayo Clinic Researchers Find New Hope for Toughest Myeloma Through Off-the-Shelf Immunotherapy

December 12th 2025

Dual-antibody, off-the-shelf therapy showed deep durable responses in patients with extra medullary multiple myeloma according to Mayo Clinic researchers.

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC

December 12th 2025

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.